JP5427409B2 - 自己免疫疾患及び移植片拒絶反応を治療するためのＩｄｅＳプロテイナーゼ（化膿連鎖球菌由来）の使用 - Google Patents

自己免疫疾患及び移植片拒絶反応を治療するためのＩｄｅＳプロテイナーゼ（化膿連鎖球菌由来）の使用 Download PDF

Info

Publication number
JP5427409B2
JP5427409B2 JP2008515137A JP2008515137A JP5427409B2 JP 5427409 B2 JP5427409 B2 JP 5427409B2 JP 2008515137 A JP2008515137 A JP 2008515137A JP 2008515137 A JP2008515137 A JP 2008515137A JP 5427409 B2 JP5427409 B2 JP 5427409B2
Authority
JP
Japan
Prior art keywords
disease
autoimmune
syndrome
ides
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008515137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008542418A (ja
Inventor
ビョーク、ラルス
ホルムダール、リカルド
ナンダクマール、クティー、セルバ
Original Assignee
ハンサ メディカル アクチボラゲット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511769A external-priority patent/GB0511769D0/en
Priority claimed from GB0605781A external-priority patent/GB0605781D0/en
Application filed by ハンサ メディカル アクチボラゲット filed Critical ハンサ メディカル アクチボラゲット
Publication of JP2008542418A publication Critical patent/JP2008542418A/ja
Application granted granted Critical
Publication of JP5427409B2 publication Critical patent/JP5427409B2/ja
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2008515137A 2005-06-09 2006-06-08 自己免疫疾患及び移植片拒絶反応を治療するためのＩｄｅＳプロテイナーゼ（化膿連鎖球菌由来）の使用 Active JP5427409B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0511769A GB0511769D0 (en) 2005-06-09 2005-06-09 Treatment
GB0511769.2 2005-06-09
GB0605781.4 2006-03-22
GB0605781A GB0605781D0 (en) 2006-03-22 2006-03-22 Treatment
PCT/EP2006/005454 WO2006131347A2 (en) 2005-06-09 2006-06-08 Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection

Publications (2)

Publication Number Publication Date
JP2008542418A JP2008542418A (ja) 2008-11-27
JP5427409B2 true JP5427409B2 (ja) 2014-02-26

Family

ID=36952007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008515137A Active JP5427409B2 (ja) 2005-06-09 2006-06-08 自己免疫疾患及び移植片拒絶反応を治療するためのＩｄｅＳプロテイナーゼ（化膿連鎖球菌由来）の使用

Country Status (14)

Country Link
US (1) US8133483B2 (enExample)
EP (1) EP1901773B1 (enExample)
JP (1) JP5427409B2 (enExample)
CN (1) CN105770871A (enExample)
AT (1) ATE548049T1 (enExample)
AU (1) AU2006256891B2 (enExample)
BE (1) BE2021C505I2 (enExample)
CA (1) CA2611646C (enExample)
ES (1) ES2380950T3 (enExample)
FR (1) FR21C1004I2 (enExample)
NL (1) NL301089I2 (enExample)
PL (1) PL1901773T3 (enExample)
PT (1) PT1901773E (enExample)
WO (1) WO2006131347A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595057B2 (en) * 2000-12-21 2009-09-29 Id Biomedical Corporation Streptococcus pyogenes antigens and corresponding DNA fragments
WO2008136735A1 (en) * 2007-05-04 2008-11-13 Nilsson Kurt G I Material for separation of a biomolecule
CA2709029A1 (en) 2007-12-21 2009-07-02 Bianca Eser Stability testing of antibodies
ES2535963T3 (es) 2009-02-09 2015-05-19 Roche Glycart Ag Análisis del patrón de glicosilación de inmunoglobulina
EP2421544B1 (en) * 2009-04-22 2015-06-03 Ofir Menashe Microorganism comprising particles and uses of same
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
AU2017214441B2 (en) * 2016-02-04 2021-08-19 Genovis Ab New Streptococcal proteases
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CA3149395A1 (en) * 2019-08-01 2021-02-04 Memorial Sloan-Kettering Cancer Center Cells for improved immunotherapy and uses thereof
KR20240007293A (ko) 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
EP4215208A4 (en) * 2020-09-21 2024-11-20 Shanghai Bao Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMBINATION AND USE THEREOF
WO2022076556A2 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
CA3216491A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
JP2024547125A (ja) * 2021-12-22 2024-12-26 上海宝済薬業股▲ふん▼有限公司 免疫グロブリン分解酵素ＩｄｅＥの変異体の用途
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
WO2024108137A2 (en) 2022-11-18 2024-05-23 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
JP2026501731A (ja) 2023-01-06 2026-01-16 サイズミック セラピューティク インコーポレイテッド プロテアーゼ変異体及びその使用
WO2025030053A1 (en) * 2023-08-01 2025-02-06 Insmed Incorporated Novel igg proteases and methods of use thereof
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
GB202413764D0 (en) 2024-09-18 2024-10-30 Genovis Ab Immunoglobulin proteases and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261585B2 (en) * 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein

Also Published As

Publication number Publication date
US20100303781A1 (en) 2010-12-02
BE2021C505I2 (enExample) 2021-05-31
ATE548049T1 (de) 2012-03-15
PL1901773T3 (pl) 2012-09-28
CA2611646A1 (en) 2006-12-14
ES2380950T3 (es) 2012-05-21
WO2006131347A3 (en) 2007-05-31
FR21C1004I1 (enExample) 2021-03-26
NL301089I1 (enExample) 2021-01-20
FR21C1004I2 (fr) 2022-01-14
AU2006256891A1 (en) 2006-12-14
JP2008542418A (ja) 2008-11-27
CA2611646C (en) 2015-08-11
CN105770871A (zh) 2016-07-20
PT1901773E (pt) 2012-06-06
AU2006256891B2 (en) 2011-08-04
NL301089I2 (nl) 2021-02-04
US8133483B2 (en) 2012-03-13
EP1901773A2 (en) 2008-03-26
EP1901773B1 (en) 2012-03-07
WO2006131347A2 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
JP2008542418A (ja) 自己免疫疾患及び移植片拒絶反応を治療するためのＩｄｅＳプロテイナーゼ（化膿連鎖球菌由来）の使用
AU2007331736B2 (en) Use of the endoglycosidase EndoS for treating immunoglobulin G mediated diseases
US5863782A (en) Synthetic mammalian sulphamidase and genetic sequences encoding same
JP3468778B2 (ja) ヒトｄｎアーゼｉ過反応性変異体
JP4451514B2 (ja) 血液凝固第ｖｉｉ因子改変体
JPS63503275A (ja) ファクター８：ｃの製造方法
JP2020171316A (ja) アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JPWO2012026309A1 (ja) 抗ｐａｄ４抗体医薬の創成
US8771700B2 (en) Interferon antagonists, antibodies thereto and associated methods of use
WO2021228052A1 (zh) 生物大分子靶向特异性补体抑制剂及其制备方法与应用
JP7607404B2 (ja) 免疫疾患を治療するためのｃ４ｂｐに基づく化合物
JP7778070B2 (ja) 免疫調節のための化合物
CN101232900B (zh) IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途
US11473069B2 (en) Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin
MXPA06012321A (es) Derivados c3 del complemento humano con funcion similar al factor de veneno de cobra.
US20240409596A1 (en) Novel immune regulator
US6524814B1 (en) Enzyme and DNA sequence encoding krill-derived multifunctional protein
WO2020232102A1 (en) Treatment of non-alcoholic steatohepatitis
WO2026017088A1 (zh) 降低受试者体内免疫球蛋白g水平的方法
JP2025513059A (ja) 組合せ治療
EP0925307A1 (en) Enzyme and dna sequence encoding same

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131023

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131202

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5427409

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250